Isis Pharmaceuticals earns $3.5m in milestone payment from Biogen Idec
IISIS-SMNRxis designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein. As per the terms of January 2012 agreement,
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
Rigosertib inhibits phosphoinositide 3-kinase and polo-like kinase, the two important cellular signaling pathways frequently activated in cancer cells. The patients who failed previous therapy with hypomethylating agents such